04th week of 2012 patent applcation highlights part 36 |
Patent application number | Title | Published |
20120020846 | INTEGRATED BIOREFINERY FOR PRODUCTION OF LIQUID FUELS - A system for the production of conversion products from synthesis gas, the system including a mixing apparatus configured for mixing steam with at least one carbonaceous material to produce a reformer feedstock; a reformer configured to produce, from the reformer feedstock, a reformer product comprising synthesis gas comprising hydrogen and carbon monoxide from the reformer feedstock; a synthesis gas conversion apparatus configured to catalytically convert at least a portion of the synthesis gas in the reformer product into synthesis gas conversion product and to separate from the synthesis gas conversion product a tailgas comprising at least one gas selected from the group consisting of carbon monoxide, carbon dioxide, hydrogen and methane; and one or more recycle lines fluidly connecting the synthesis gas conversion apparatus with the mixing apparatus, the reformer, or both. | 2012-01-26 |
20120020847 | Retention Of Solid Powder Catalyst By In-Situ Cross Flow Filtration In Continuous Stirred Reactors - A system for the retention of finely divided solid catalysts inside a continuously stirred back-mixed reactor is presented. The system includes multiple porous media filter elements and multiple reactor baffles. The porous media filter elements are located to act as part of said reactor baffles. The porous media is selected to retain the large majority of the catalyst particles while allowing the reacted contents to leave the reactor through the pores of the porous media. The porous media elements may have a circular cross-section. The system utilizes the pumped flow of the reactor's agitator system to sweep solids from the porous media, and a high velocity zone is created around the back side of the porous media filter elements by a venturi effect caused by design and placement of the baffles and the porous media elements. | 2012-01-26 |
20120020848 | HYDROGEN PEROXIDE VAPORIZER - An apparatus for decontaminating articles comprised of:
| 2012-01-26 |
20120020849 | AUTOMATIC TONOMETER TIP DISINFECTION APPARATUS - A tonometer tip disinfection apparatus for disinfecting and rinsing a tonometer tip includes a first basin configured to hold a disinfecting solution, a second basin configured to hold a rinsing solution, a holding platform configured to receive at least one tonometer tip, a tonometer tip support arm configured to support a tonometer tip having a tip end in an orientation allowing the tip end to reside at least in part within the first and second basins, and a transportation assembly configured to automatically move the tonometer tip support arm between the first and second basins and the holding platform. | 2012-01-26 |
20120020850 | CRYSTALLIZATION SYSTEM AND METHOD FOR PROMOTING CRYSTALLIZATION - A crystallization system includes a well plate and a cover for the well plate, at least one of the well plate and said cover includes at least a transparent window. The well plate including at least one well comprising a bottom surface including a first essentially planar bottom surface section and a second essentially planar bottom surface section in a first bottom plane and a well border wall provided by a well border edge surrounding the planar bottom surface section: The cover includes a first essentially planar top surface section in a first top plane adapted to face the first essentially planar bottom surface section. The first and the second essentially planar bottom surface sections are totally or partly separated by a liquid barrier, provided by one or more of a low tension surface barrier, a ridge and an indentation. A method of producing the crystallization system includes providing a bottom plate, a perforated plate and a cover, mounting the bottom plate to the perforated plate to provide a well plate including a plurality of wells each having a bottom surface. The system is simple and cost effective to produce and simple to handle. | 2012-01-26 |
20120020851 | Reformer Apparatus and Method - A multiple adiabatic bed reforming apparatus and process involving stage-wise combustion and multiple reforming chambers. Co-flow and cross-flow occurs under laminar flow conditions. A reformer suitable for small scale production as well as large scale production. A passive stage-by-stage fuel distribution network suitable for low pressure fuel wherein the resistances in successive fuel distribution lines control the amount of fuel delivered to each combustion stage. Heat is captured from reforming syngas product to preheat gases before entering the reformer. Conditions that would produce unwanted coking or metal dusting are avoided or localized away from the heat exchangers to locations which can be cost effectively protected. A chemical reactor which has a core composed of a stack of metal plates that are diffusion bonded in face-to-face relationship. | 2012-01-26 |
20120020852 | ETHYLENE CRACKING FURNACE - An ethylene cracking furnace comprising a high pressure steam drum ( | 2012-01-26 |
20120020853 | METHOD OF MANUFACTURING ALUMINA BY RECYCLING NICKEL-ALUMINUM - A method of manufacturing alumina by recycling nickel-aluminum comprises a step of “soaking,” by soaking a purified mineral of nickel-aluminum into an alkaline buffer followed by keeping at an environment of 1 ATM to obtain a rough solution of aluminate; a step of “filtration,” by filtering out a purified mineral of nickel and cobalt from the rough solution of aluminate to obtain a solution of aluminate; a step of “purification,” by adding a de-impurity reagent into the solution of aluminate to remove the impurity of vanadates, molybdates and silicates from the solution of aluminate, in order to obtain a purified solution of aluminate; a step of “sedimentation,” by precipitating out aluminum hydroxide from the purified solution of aluminate; and a step of “calcination,” by calcining the aluminum hydroxide, finally to obtain alumina. | 2012-01-26 |
20120020854 | METHOD, SYSTEM AND APPARATUS FOR LIQUID INJECTION INTO A GAS SYSTEM - A method for injection of a liquid reductant ( | 2012-01-26 |
20120020855 | Flow-Through Substrates and Methods for Making and Using Them - Flow-through substrates, such as honeycombs, comprising certain zeolites. The flow-through substrates may be used, for example, in the removal of a heavy metal from a fluid such as a gas stream. | 2012-01-26 |
20120020856 | ENHANCED ADSORBENTS AND METHODS FOR MERCURY REMOVAL - A flue gas adsorbent and method for making an adsorbent for mercury capture are disclosed. The adsorbent comprises an admixture of an adsorptive material and an additive that have been physically combined thereby eliminating the need for traditional impregnation. A method for removing mercury from a flue gas stream is also disclosed. | 2012-01-26 |
20120020857 | DOSING SYSTEM HAVING RECIRCULATION HEATING AND VACUUM DRAINING - A reductant dosing system is disclosed. The reductant dosing system may have a supply of reductant, a reductant nozzle, and a pump with an inlet and an outlet. The reductant dosing system may also have a first passage connecting the supply with the inlet of the pump, and a first control valve disposed in the first passage. The reductant dosing system may further have a second passage connecting the outlet of the pump with the reductant nozzle, and a second control valve disposed in the second passage. The reductant dosing system may additionally have a third passage connecting the second control valve to the first passage at a location downstream of the first control valve, and a fourth passage connecting the second control valve with the supply. | 2012-01-26 |
20120020858 | HIGH-EFFICIENCY CATALYTIC CONVERTERS FOR TREATING EXHAUST GASES - Several embodiments of high-efficiency catalytic converters and associated systems and methods are disclosed. In one embodiment, a catalytic converter for treating a flow of exhaust gas comprising a reaction chamber, a heating enclosure enclosing at least a portion of the reaction chamber, and an optional coolant channel encasing the heating enclosure. The reaction chamber can have a first end section through which the exhaust gas flows into the reaction chamber and a second end section from which the exhaust gas exits the reaction chamber. The heating enclosure is configured to contain heated gas along the exterior of the reaction chamber, and the optional coolant channel is configured to contain a flow of coolant around the heating enclosure. The catalytic converter can further include a catalytic element in the reaction chamber. | 2012-01-26 |
20120020859 | Method for Capturing Carbon Oxides with a View to Subsequently Storing Same - The present invention relates to a method for capturing carbon oxides, in particular for recovering carbon oxides from an industrial facility, and specifically to a method for capturing CO | 2012-01-26 |
20120020860 | APPARATUS AND METHOD FOR SEQUESTERING FLUE GAS CO2 - A fluidized bed reactor device for sequestering flue gas CO | 2012-01-26 |
20120020861 | USE OF A TiO2- BASED COMPOSITION FOR CAPTURING HALOGENATED COMPOUNDS CONTAINED IN A GASEOUS MIXTURE - The invention is concerned with the use of a TiO | 2012-01-26 |
20120020862 | METHOD FOR THE REMOVAL OF HYDROGEN FROM A HYDROGEN SENSITIVE DEVICE BY MEANS OF A NON-EVAPORABLE YTTRIUM BASED GETTER ALLOY - Getter alloys particularly suitable for hydrogen sorption are described. The getter alloys include a first element consisting of yttrium or a yttrium equivalent mixture, the first element forming at least 30% by atoms of the alloy. A method for removing hydrogen from devices which are sensitive to the presence thereof and hydrogen-sensitive devices which contain the described getter alloys are also described. | 2012-01-26 |
20120020863 | METHOD FOR PROCESSING CERAMIC FIBERS - A method of treating ceramic fibers based on metal carbide, the method including a first reagent gas heat treatment performed with at least one first reagent gas of the halogen type that chemically transforms the surface of the fiber to obtain a surface layer constituted mainly of carbon, and a second reagent gas heat treatment performed with at least one second reagent gas that eliminates the surface layer formed during the chemical transformation. | 2012-01-26 |
20120020864 | Hydride Compounds with Silicon and Germanium Core Atoms and method of Synthesizing Same - A method is provided for synthesizing silicon-germanium hydride compounds of the formula (H | 2012-01-26 |
20120020865 | METHOD AND APPARATUS FOR PURIFYING METALLURGICAL SILICON FOR SOLAR CELLS - A method for improving yield of an upgraded metallurgical-grade (UMG) silicon purification process is disclosed. In the UMG silicon (UMGSi) purification process, in a reaction chamber, purification is performed on a silicon melt therein by one, all or a plurality of the following techniques in the same apparatus at the same time, including: a crucible ratio approach, the addition of water-soluble substances, the control of power, the control of vacuum pressure, the upward venting of exhaust, isolation by high-pressure gas jet, and carbon removal by sandblasting, thereby reducing oxygen, carbon and other impurities in the silicon melt, meeting a high-purity silicon standard of solar cells, increasing yield while maintaining low cost, and avoiding EMF reduction over time. An exhaust venting device for purification processes is also disclosed, which allows exhaust to be vented from the top of the reactor chamber, thereby avoiding backflow of exhaust into the silicon melt and erosion of the reactor. | 2012-01-26 |
20120020866 | METHOD OF PROCESSING LIQUID CHLORINE CONTAINING NITROGEN TRICHLORIDE - A method of processing a stream of liquid chlorine containing nitrogen trichloride from a chloralkali plant. The liquid stream is received into a vaporizer in which it is evaporated 1O1 chlorine gas and nitrogen trichloride gas. The gas stream is processed by destroying the nitrogen trichloride gas, for example in a superheater or a catalytic bed. The processed gas stream is recycled to the chlorine production train of the chloralkali plant. The process avoids the use of organic solvents to decompose the nitrogen trichloride and the creation of a waste stream requiring further handling. | 2012-01-26 |
20120020867 | Method for Producing Imide Compound - Disclosed is a method for producing “a salt or a complex comprising imide and an organic base”, characterized by reacting halogenated sulfuryl or halogenated phosphoryl with ammonia in the presence of an organic base. According to this method, a target imide compound can be produced in a high yield while significantly suppressing the production of by-products. Further, by reacting the obtained imide compound with an alkali metal hydroxide or an alkaline earth metal hydroxide, an imide metal salt can be easily derived. | 2012-01-26 |
20120020868 | PROCESS AND INSTALLATION FOR PRODUCING SUBSTITUTE GAS - A process and an installation for reducing particulate material containing iron oxide are shown, wherein the material containing iron oxide is at least partially reduced with reducing gas in a reducing zone and the waste gas produced during the reduction is drawn off and subsequently subjected to CO | 2012-01-26 |
20120020869 | Microporous and Mesoporous Carbon Xerogel Having a Characteristic Mesopore Size and Precursors Thereof and Also a Process for Producing These and Their Use - The invention relates to a microporous and mesoporous carbon xerogel and organic precursors thereof based on a phenol-formaldehyde xerogel. A characteristic parameter common to carbon xerogels is a peak in the mesopore size distribution determined by the BJH method (Barrett-Joyner-Halenda) from nitrogen absorption measurements at 77 K in the range from 3.5 nm to 4 nm. The production process is characterized firstly by the low starting material costs (use of phenol instead of resorcinol) and secondly by very simple and cost-effective processing; convective drying without solvent exchange instead of supercritical drying or freeze drying. The carbon xerogels and their organic phenol-formaldehyde xerogel precursors have densities of corresponding to a porosity of up to 89%, and the xerogels can also have a relevant mesopore volume. The carbon xerogels obtained from the phenol-formaldehyde xerogels are also microporous. | 2012-01-26 |
20120020870 | PROCESS TO PRODUCE CARBON NANOTUBES FROM MICROALGAE - We disclose a process to produce carbon nanotubes from microalgae. Microalgae is been utilized for biodiesel production. The algal membrane resulted from oil extraction of microalgae is used here to produce carbon nanotubes. The process utilized for the conversion is composed of two steps, in the first step the algal membrane is converted to carbon black through a pyrolysis process in inert atmosphere, in the second step the resulted carbon black is converted to carbon nanotubes by mixing the carbon black with a fluid with known self ignition condition and subjecting the mix to said self ignition condition. | 2012-01-26 |
20120020871 | METHOD AND APPARATUS FOR MANUFACTURING PERCHLORATE - The invention relates to a method of manufacturing a perchlorate including an electrolysis process (S | 2012-01-26 |
20120020872 | HIGH TEMPERATURE REDUCTION OF HYDROGEN PEROXIDE CATALYST FOR IMPROVED SELECTIVITY - Method for making a direct synthesis hydrogen peroxide catalyst includes (i) mixing together a solvent, a plurality of noble metal catalyst atoms, and a plurality of organic dispersing agent molecules, the organic dispersing agent molecules each including at least one functional group capable of bonding with the noble metal catalyst atoms; (ii) reacting the organic dispersing agent with the catalyst atoms to form complexed catalyst atoms and forming a plurality of catalytic nanoparticles from the complexed catalyst atoms; (iii) supporting the catalytic nanoparticles on a support material; and (iv) reducing the catalyst atoms at a temperature of at least 351° C. to yield a supported and activated direct synthesis hydrogen peroxide catalyst. | 2012-01-26 |
20120020873 | METHOD AND APPARATUS FOR PRODUCTION OF HYDROGEN FROM METHANOL - Method of producing hydrogen from methanol comprising providing a feed mixture of methanol and water at high pressure, delivering the feed mixture to a reactor chamber ( | 2012-01-26 |
20120020874 | PROCESS FOR PRODUCING HYDROGEN FROM METHANOL - The invention is directed to a process for producing hydrogen from methanol, comprising providing at least one flow of methanol and (1) catalytically converting part of the methanol or a fuel gas with air oxygen to carbon dioxide and water, while generating heat and (2) catalytically converting the methanol or the remaining part of the methanol at elevated temperature to hydrogen and carbon monoxide, followed by conversion of the carbon monoxide with water to hydrogen and carbon dioxide, wherein the heat generated in step (1) is sufficient to produce the elevated temperature required in step (2), wherein both steps (1) and (2) are carried out in a bed of sintered metal particles, the bed of sintered metal in step (2) having a surface that is catalytically active for the conversion of methanol to hydrogen, and wherein the beds of sintered metal particles are in heat exchanging relationship. | 2012-01-26 |
20120020875 | CATALYST FOR REDUCING NITROGEN OXIDES AND METHOD FOR PRODUCING THE SAME - The object is to provide an exhaust gas reduction catalyst that exhibit high nitrogen oxide reduction performance, and to provide a simple and efficient method for producing the catalyst, in which the amount of the waste liquid is reduced, further, an object of the invention is to provide a zeolite-containing catalyst for reducing nitrogen oxides, which does not use an expensive noble metal or the like and which has high nitrogen oxide reduction performance. The present invention relates to a catalyst for reducing nitrogen oxides, which comprises: zeolite at least containing an aluminium atom and a phosphorus atom in the framework thereof; and a metal supported on the zeolite, wherein a coefficient of variation of intensity of the metal is at least 20%, when performing an elemental mapping of the metal in the catalyst with an electron probe microanalyzer, and, a catalyst for reducing nitrogen oxides, which comprises the zeolite containing at least a silicon atom, a phosphorus atom and an aluminium atom, and having an adsorption retention rate of at least 80% in a water vapor cyclic adsorption/desorption test at 90° C. | 2012-01-26 |
20120020876 | HEDGEHOG PATHWAY INHIBITORS - This disclosure generally relates to methods useful for improving, for example, blood vessel density and/or blood vessel patency to a tissue by administration of a hedgehog pathway inhibitor. In certain embodiments, the hedgehog pathway inhibitor is administered with an agent to improve the delivery of the agent to the tissue. In certain embodiments, the tissue comprises tumor tissue. | 2012-01-26 |
20120020877 | PROCESS AND INTRA-CERVICAL DEVICE FOR THE LOCAL RELEASE OF DRUGS IN THE LOCAL-REGIONAL TREATMENT OF CERVICAL CANCER - An intrauterine device and more specifically an intracervical device (ICD) for the local release of drugs in the loco-regional treatment of tumours of the uterine cervix comprises an elongated stem ( | 2012-01-26 |
20120020878 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS - The present invention comprises a method for delivering pharmaceutical and/or imaging agents within and/or through the dermal, mucosal and other cellular membranes, and across the blood-brain barrier, utilizing a fusogenic protein. The fusogenic protein is associated with a phospholipid membrane, such as a liposome. The liposome may include dioleoylphosphatidylserine, a negatively charged long-chain lipid. Alternatively, the liposome is comprised of a mixture of negatively charged long-chain lipids, neutral long-chain lipids, and neutral short-chain lipids. Preferred fusogenic proteins include saposin C and other proteins, polypeptides and peptide analogs derived from saposin C. The active agent contained within the liposome may comprise biomolecules and/or organic molecules. This technology can be used for both cosmetic and medicinal applications in which the objective is delivery of the active agent within and/or beneath biological membranes or across the blood-brain barrier and neuronal membranes. | 2012-01-26 |
20120020879 | PROCESS, COMPOSITION AND METHOD FOR ANION DEPOSITION INTO FERRITIN FOR THERAPEUTIC AND OTHER USE - Provided herein is a process for production of a metal nanoparticle, the process comprising providing a first solution containing a protein nanocage complex comprising a hydrophobic metal core and an ion-transport mechanism, providing a second solution containing a preselected anionic agent, combining the first and second solutions into a third combined solution, and applying an external method to the third combined solution to manipulate the metal core's redox state, in which reduction of the metal core causes the preselected anionic agent to be imported and incorporated into the metal core. Also provided herein is a composition from the process and a method of use. | 2012-01-26 |
20120020880 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 2012-01-26 |
20120020881 | Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes - This invention relates to novel compounds suitable for labeling by positron emitting isotopes, such as | 2012-01-26 |
20120020882 | PEPTIDE-BASED COMPOUNDS - The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors. | 2012-01-26 |
20120020883 | Methods and compositions for detection of bacteria and treatment of diseases and disorders - Described herein are methods for detecting a bacteria in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using bacteria. The methods can be used in conjunction with methods for treating a disease, disorder or condition. Such sites, diseases and disorders include sites of cellular proliferation, such as tumors, tumor tissues, metastases, areas of inflammation, immunoprivileged sites or tissues, wounds and infections. Further described are bacteria for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a bacterium. Bacteria described herein include those that bind, sequester or accumulate radiolabeled compounds by expression of an endogenous gene product that binds to the radiolabeled compound. Additional imaging and therapeutic agents and methods also are described. | 2012-01-26 |
20120020884 | INDOLE DERIVATIVES - An indole-based in vivo imaging agent is provided by the present invention that binds with high affinity to PBR, has good uptake into the brain following administration, and which has good selective binding to PBR. The invention also includes a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. Also provided is a cassette for automated synthesis of the in vivo imaging agent. Further aspects of the invention include a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, and methods for the use of said in vivo imaging agent. | 2012-01-26 |
20120020885 | MHC-Less cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject. | 2012-01-26 |
20120020886 | THERMAL SPIN CROSS-OVER COMPOUNDS AND METHODS OF USING SAME - A compound has the of Formula I or a salt thereof: | 2012-01-26 |
20120020887 | Use of Simple Amino Acids to Form Porous Particles - Particles having a tap density of less than 0.4 g/cm | 2012-01-26 |
20120020888 | BIOMARKER - Described are bladder cancer specific biomarkers and lung cancer specific biomarkers comprising the nucleic acid sequence of the Engrailed-2 (EN2) gene or the amino acid sequence of the encoded EN2 protein. Also described are uses of the biomarkers in the treatment, diagnosis, monitoring and imaging of bladder cancer and lung cancer. | 2012-01-26 |
20120020889 | Polypeptides Targeting Vascular Endothelial Growth Factor Receptor-2 and Alpha V Beta 3 Integrin - Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization. | 2012-01-26 |
20120020890 | STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS - The invention provides proteins from | 2012-01-26 |
20120020891 | METABOLITES FOR ORAL HEALTH AND USES THEREOF - The present invention provides various methods of using metabolite profiles correlated with periodontal disease or a health oral status for the diagnosis of periodontal disease, identification of responders and, or non-responders to therapeutic agents for periodontal disease, a method to test the efficacy of test compounds to prevent periodontal disease. The present invention also provides for a dentifrice composition containing an effective amount of a metabolite therapeutic agent which brings about a greater change in metabolite levels compared to a control dentifrice composition. | 2012-01-26 |
20120020892 | FORCE-INDUCED MAGNETIZATION CONTRAST FOR DIAGNOSIS AND IMAGING - A method of detecting target molecules comprising; conjugating a first magnetic particle to a first ligand to form a first magnetic particle ligand conjugate; adding the conjugate to a sample containing target molecules to form a mixture comprising, the free conjugate and conjugate-target molecule binding pairs; measuring a first magnetization of the mixture; subjecting the mixture to a first force; measuring a second magnetization value of the mixture; subtracting the second magnetization value from the first magnetization value to calculate a first force-induced magnetization contrast; subjecting the mixture to a second force; measuring a third magnetization of the mixture; and subtracting the third magnetization value from the second magnetization value to calculate a second force-induced magnetization contrast. | 2012-01-26 |
20120020893 | Intravascular Imaging Device and Uses Thereof - The invention is directed to a probe-type imaging device useful to visualize interior surfaces, e.g., the lumen of blood vessels. Specifically, the probe-type device is particularly useful for direct tissue imaging in the presence or absence of molecular imaging agents. | 2012-01-26 |
20120020894 | Production of Targeted MRI Probes by Biocompatible Coupling of Macromolecules with Charged Nanoparticles - The present invention relates to the production of marker particles, which are especially useful for target-specific molecular magnetic resonance imaging (MRI), using charged iron oxide nanoparticles and inversely charged peptides covalently linked to macromolecules, which are capable of binding to a specific type of cells. | 2012-01-26 |
20120020895 | BEAR BILE MACROMOLECULAR EXTRACT AND PREPARATION METHOD AND USE THEREOF - A bear bile macromolecular extract with anti-HCV virus function is disclosed. A preparation method comprises the following steps of: taking fresh bear bile or dissolving bear bile powder with water, centrifuging it by a molecular sieve filter membrane with molecular weight cut-off of 100,000 or an ultrafiltration membrane, filtering to obtain sediment, dissolving the sediment with water, adding the solution to sephadex column, separating the solution by using water or buffer as elution solvent, and freeze-drying the eluent to obtain the bear bile macromolecular extract. Experiments show that the bear bile macromolecular extract has anti-HCV virus function and can be used for treating hepatitis C. | 2012-01-26 |
20120020896 | ANTI-BIOFILM CARBONATE COMPOUNDS FOR USE IN ORAL CARE COMPOSITIONS - The present invention includes oral care compositions and methods for inhibiting growth and formation of oral biofilms by quorum sensing inhibition and/or bactericidal activity. In some embodiments, the present invention discloses an oral care composition including a therapeutically effective amount of at least one carbonate compound of Formula (1) and at least one excipient: wherein, R | 2012-01-26 |
20120020897 | DENTIFRICE COMPOSITION - The invention encompasses a dentifrice composition comprising an orally acceptable vehicle; a source of zinc ions; and a polysaccharide thickening agent, the polysaccharide thickening agent having at most 0.5 charged groups per sugar residue unit along the polysaccharide backbone such as xanthan gum and/or hydroxyethyl cellulose. | 2012-01-26 |
20120020898 | NON-AQUEOUS DENTIFRICE COMPOSITION WITH BIOACCEPTABLE AND BIOACTIVE GLASS AND METHODS OF USE AND MANUFACTURE THEREOF - The invention encompasses non-aqueous dentifrice compositions containing a bioacceptable and bioactive glass with improved mouth-feel, foam, and product stability. More particularly, the invention encompasses non-aqueous compositions including combinations including carrageenan and/or carboxymethylcellulose gums, glycerin, ethylene oxide/propylene oxide copolymers, and a bioactive glass and methods of use the compositions in an oral care product, for example, a whitening tooth-paste, for hypersensitive teeth. | 2012-01-26 |
20120020899 | ORAL COMPOSITIONS FOR TREATING TOOTH SENSITIVITY AND METHODS OF USE AND MANUFACTURE THEREOF - The invention encompasses oral care compositions comprising one or more active component and one or more adhesive polymers, which cause the active component to adhere to the tooth surface. In certain embodiments the active agent is an occlusion agent. The invention also encompasses methods of treating the teeth or a teeth surface with an active agent. In certain embodiments, the invention encompasses treating the teeth with an occlusion agent to prevent or alleviate tooth sensitivity. | 2012-01-26 |
20120020900 | DENSENSITIZING DENTIFRICE EXHIBITING DENTAL TISSUE ANTIBACTERIAL AGENT UPTAKE - An oral composition exhibiting increased uptake by dental tissue of antibacterial compounds contained therein and eliminating or substantially reducing the discomfort and pain associated with dentinal hypersensitivity. The composition includes an orally acceptable vehicle for such composition, an effective therapeutic amount of an antibacterial compound, a mixture of anionic surfactant and amphoteric surfactant, the mixture having 0.1 wt. % to 2.0 wt. % anionic surfactant and 0.8 wt. % to 2.0 wt. % amphoteric surfactant, and a potassium ion releasable compound. | 2012-01-26 |
20120020901 | ORAL CARE COMPOSITIONS - The invention relates to desensitizing, anti-tartar oral care compositions comprising an orally acceptable vehicle and an effective desensitizing and anti-tartar amount of tetrapotassium pyrophosphate. | 2012-01-26 |
20120020902 | PHARMACEUTICAL, DERMATOLOGICAL, NUTRITIONAL OR COSMETIC COMPOSITION FOR COMBATING THE IMMUNOSUPPRESSIVE ACTION OF AGGRESSIVE AGENTS ON THE SKIN - The object of the invention is a mixture of catechin and quercetin in a molar ratio varying between 3:1 and 6:1, respectively, for the treatment of the immunosuppression induced in the skin by aggressive agents such as airborne pollutants, dehydrating agents, ultraviolet radiation, and thermal and osmotic shocks, and a pharmaceutical, dermatological, nutritional or cosmetic composition containing said mixture as an active ingredient. | 2012-01-26 |
20120020903 | COSMETIC COMPOSITION CONTAINING A PARTICULAR WATER, AND USE THEREOF AS A DEPIGMENTING OR ANTI-AGEING AGENT - The invention relates to the use, in a cosmetic or dermatological composition, of a particular water having a pH of between 7.8 and 10 and a total dissolved solids (TDS) concentration of between 10 and 250 mg/l. The invention also relates to a cosmetic or dermatological composition containing this water. | 2012-01-26 |
20120020904 | NOVEL PROTEASOME-ACTIVATING LIGHTENING PEPTIDES AND COMPOSITIONS CONTAINING SAME - The present invention relates to depigmenting, lightening and/or whitening peptidic compounds of general formula (I) | 2012-01-26 |
20120020905 | Human sample matching system - Methods and apparatus for a human sample (S), analyzing the sample (S) and then determining a match with a member of the opposite sex is disclosed. In one embodiment, a customer purchases an AromaMatch™ Test Kit ( | 2012-01-26 |
20120020906 | ANTIPERSPIRANT SPRAYS WITH ESTER OILS - Antiperspirant compositions for personal body care, formulated as a suspension which can be sprayed with or without a propellant, include at least one antiperspirant substance, 0-5 wt. % free water, based on the weight of the propellant-free composition, at least one ester, and at least one additional cosmetic oil which is liquid under normal conditions, as a carrier. | 2012-01-26 |
20120020907 | LONG-WEAR MASCARA COMPOSITION - The present invention is directed to long wearing, water-resistant mascara including an oil-soluble polar modified polymer and an amine compound. | 2012-01-26 |
20120020908 | PROCESS FOR MAKING STABLE HIGH VISCOSITY AMINO SILICONE EMULSION - A stable highly viscous aminosilicone polymeric fluids and a process for synthesis of stable high viscosity amino silicone emulsion by using the said aminosilicone polymeric fluid by way of a simple and cost-effective manufacturing process yielding emulsions in large scale commercial process with a particle size from 0.01 micron to 150 micron for diverse applications such as in personal care, specially hair care, textile, release and alike. | 2012-01-26 |
20120020909 | Organopolysiloxane Emulsions and Their Production - This invention relates to aqueous emulsions comprising a polyorganosiloxane and a wax, and to methods of production of such emulsions. The emulsions are of the type oil-in-water. An organopolysiloxane is polymerized in admixture with a molten wax, thereby forming a blend of the wax with an organopolysiloxane of increased molecular weight, and the said blend of polymer and molten wax is emulsified in water in the presence of a surfactant. The emulsions are useful in personal care applications such as on hair, skin, mucous membrane or teeth. The emulsions are also useful in applications such as paints, water based coatings, textile fibre treatment, leather lubrication, fabric softening, fabric care in laundry applications, homecare, release agents and oil drag reduction. | 2012-01-26 |
20120020910 | Compositions for Preserving the Human or Animal Body - The present invention relates to a novel composition, for nontherapeutic purposes, containing at least one POM (PolyOxyMethylene dialkyl ether) and at least one diol. It also relates to the use of this composition for preserving and/or embalming a human or animal body. | 2012-01-26 |
20120020911 | MATRIX COMPOSED OF A NATURALLY-OCCURRING PROTEIN BACKBONE CROSS LINKED BY A SYNTHETIC POLYMER AND METHODS OF GENERATING AND USING SAME - The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration. | 2012-01-26 |
20120020912 | PROSTATE CANCER VACCINE - Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines. | 2012-01-26 |
20120020913 | METHODS FOR PANCREATIC TISSUE REGENERATION - Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of a TWEAK receptor agonist. These methods may be used to treat diseases or conditions where enhancement of pancreatic progenitor cells for cell replacement therapy is desirable, including, e g, diabetes and conditions that result in loss of all or part of the pancreas | 2012-01-26 |
20120020914 | LEUKEMIA INHIBITORY FACTOR (LIF) FOR USE IN REPRESSING HUMAN PAPILLOMAVIRUS (HPV) TRANSCRIPTION - Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated genital, anal, vulvar, penile, oral, or laryngeal wart, for treating HPV-associated cervical dysplasia or cervical cancer, and for repressing HPV transcription, by administering LIF to a patient in need thereof. A related embodiment is treatment of HPV-16 by use of LIF. | 2012-01-26 |
20120020915 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System - Disclosed are compounds of the general formula (I): | 2012-01-26 |
20120020916 | USE OF IL-12 AND IL-12 ANTAGONISTS IN THE TREATMENT OF AUTOIMMUNE DISEASES - Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease. | 2012-01-26 |
20120020917 | METHODS FOR ACCELERATING WOUND HEALING BY ADMINISTRATION OF ADIPOKINES - Methods for inducing or accelerating a healing process of a damaged skill or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or transforming the skin cells colonizing the damaged skin or skin wound such as to express and secrete an adipokine, thereby inducing or accelerating the healing process of the damaged skin or skin wound. | 2012-01-26 |
20120020918 | IL-1 FAMILY VARIANTS - The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins. | 2012-01-26 |
20120020919 | METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2012-01-26 |
20120020920 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR - The present invention relates to a fused ring compound represented by the following formula [I] | 2012-01-26 |
20120020921 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT - Provided are prodrugs of pyrrolo[1,2-f][1,2,4]triazin-7-yl nucleoside phosphates wherein the 1′ position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections. | 2012-01-26 |
20120020922 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES - Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. | 2012-01-26 |
20120020923 | Method of treating viral diseases with combinations of TPO receptor agonist and anti-viral agents - Invented is a method of treating viral diseases, particularly hepatitis C, in a human, in need thereof which comprises the administration of a combination of therapeutically active agents selected from a TPO receptor agonist and an antiviral therapy selected from: an alpha interferon, ribavirin, a ribavirin analog and an HCV antiviral to such human. | 2012-01-26 |
20120020924 | NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A REDUCED SIDE EFFECT - The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector. | 2012-01-26 |
20120020925 | Therapeutic Use of Specialized Endothelial Progenitor Cells - The invention relates to products, processes, and therapeutic methods for restoring blood flow to tissues at risk of becoming or being ischemic by inducing angiogenesis and/or vasculogenesis in tissues in need thereof by administering endothelial colony forming cells alone or in combination with other cell types and/or agents. In one aspect, the invention is useful for inducing angiogenesis and/or vasculogenesis in patients with ischemic disease including ischemic heart disease, and other ischemic vascular disorders. | 2012-01-26 |
20120020926 | COMPOSITION COMPRISING CAFTARIC ACID AND/OR DERIVATIVES THEREOF - The present invention relates generally to the field of food and drinks. In particular, for example, a composition is provided that allows to provide tartaric and/or caffeic acid to a subject. One embodiment of the present invention is a composition comprising an ingredient containing caftaric acid and/or derivatives thereof, and a lactic acid bacterium capable of hydrolysing caftaric acid and/or derivatives thereof to generate tartaric and/or caffeic acid. | 2012-01-26 |
20120020927 | Bacterial Strains Having an Outstanding Ability to Produce Menaquinone - The invention relates to bacterial strains having an outstanding ability to produce menaquinone and to applications thereof. | 2012-01-26 |
20120020928 | GRANULES CONTAINING FILAMENTARY FUNGI AND METHOD OF PREPARATION THEREOF - In a method for preparing granules containing filamentary fungi, a filamentary fungi culture is mixed with at least one modified starch and a starchy flour, then fillers and possible nutrients are added to the obtained product, obtaining a paste that is subsequently subjected to granulation and drying. | 2012-01-26 |
20120020929 | METHODS AND COMPOSITIONS RELATING TO NEURONAL CELL AND TISSUE DIFFERENTIATION - The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules. | 2012-01-26 |
20120020930 | METHODS FOR THE PREPARATION OF ADIPOSE DERIVED STEM CELLS AND UTILIZING SAID CELLS IN THE TREATMENT OF DISEASES - The present invention provides a method for the preparation of adipose derived stem cells for use in cellular therapy. In further aspects the present invention provides cells produced by the method of the invention, pharmaceutical compositions and kits suitable for use in treatment of patients. | 2012-01-26 |
20120020931 | THERAPEUTIC ENCAPSULATED EMBRYONIC STEM CELLS AND MESENCHYMAL STROMAL CELLS - This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (ES) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (RA) into the permeable microcapsule system. This application also discloses a micro-encapsulation system for immobilizing mesenchymal stromal cells (MSCs) while sustaining the molecular communication. Thus, the invention provides the use of encapsulated mesenchymal stromal cells in the cellular transplantation therapies. Moreover, the invention provides methods for delivery of encapsulated MSCs into the central nervous system and therapies derived therefrom, such as, the treatment of spinal cord injury (SCI) and other inflammatory conditions. | 2012-01-26 |
20120020932 | THERMOSENSITIVE HYDROGEL COMPOSITION AND METHOD - A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment. | 2012-01-26 |
20120020933 | METHOD OF NERVE REPAIR WITH AMNION AND CHORION CONSTRUCTS - Improved methods for the surgical repair of a damaged or severed nerve are described. The improvement includes covering the surgically repaired nerve or a damaged neurilemma with at least one of an amniotic fluid and a construct, or replacing the damaged neurilemma with the construct prior to wound closing during the surgery. The construct contains an allograft having at least one layer of amnion and chorion tissues, and a shape adapted for enclosing a damaged or severed nerve or for covering or replacing the damaged neurilemma during the surgical repair. The products and methods improve the performance of the nerve surgery, e.g., by reducing inflammation, inhibiting fibrosis, scarring, fibroblast proliferation, post-operative infection while also promoting more rapid healing of damaged or traumatized nerve structures. | 2012-01-26 |
20120020934 | MATERIALS AND METHODS FOR CRYOPRESERVED BONE CONSTRUCTS - The subject invention concern materials and methods for cryopreservation of HCG-cell constructs. In one embodiment, porous HCG scaffolds are provided in a perfusion bioreactor having perfusion chambers that can contain the HCG scaffolds, cells are then seeded in the HCG scaffolds in the perfusion bioreactor, cell culture media is perfused through and the bioreactor operated so as to allow for cell seeding and growth in the HCG scaffold. After a suitable period of time, the cell culture media is removed and the HCG containing cells (HCG-cell constructs) can be washed with a suitable buffer, such as phosphate-buffered saline (PBS). The HCG-cell constructs are then perfused in the bioreactor with a suitable cryopreservation fluid. The cryopreservant can comprise one or more of the following: DMSO, trehalose, glycerol, ethylene glycol, and serum for cell culture (e.g., fetal bovine serum (FBS)). In one embodiment, the HCG-cell constructs are perfused for a suitable period of time with cryopreservant fluid using transverse flow of the fluid in the bioreactor at a suitable flow rate. The HCG-cell constructs (or the perfusion chambers containing them) are then removed from the bioreactor and placed in a cryopreservant media and maintained at increasingly colder temperatures until temperatures reach about −80° C. The frozen HCG-cell constructs (or the chambers containing them) can then be stored at a suitable cryogenic temperature (e.g., in liquid nitrogen) until needed. When needed, frozen HCG-cell constructs can be removed from cold storage and thawed using suitable means (e.g., 37° C. water bath). Cells contemplated for use in the present invention include stem cells, such mesenchymal stem cells. Cells can be animal cells, such as mammalian cells. In one embodiment, the cells are human cells. | 2012-01-26 |
20120020935 | CARDIAC STEM CELLS AND METHODS FOR ISOLATION OF SAME - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs. | 2012-01-26 |
20120020936 | TREATMENT OF NEURODEGENERATIVE DISEASE USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 2012-01-26 |
20120020937 | AUTOLOGOUS AND ALLOGENIC ADIPOSE-DERIVED STROMAL STEM CELL COMPOSITION FOR TREATING FISTULAS - The present invention relates to a method for producing clinically effective quantities of human adipose tissue-derived stromal cells for treating fistulas and a composition made with the same. The method of the present invention can efficiently produce clinically effective number of adipose tissue-derived stromal cells within a short period by improving conventional standard culturing methods. The adipose stem cells composition containing the adipose tissue-derived stromal cells obtained by the method of the present invention exhibit superior multipotency and immunomodulatory activity over those of a cell composition produced by conventional methods, and thus is more suitable for treating fistulas. The cell composition of the present invention has excellent clinical usages especially since immune response is suppressed in allogenic adipose-derived stem cells. | 2012-01-26 |
20120020938 | MHC- less cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject. | 2012-01-26 |
20120020939 | MHC-less cells - The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject. | 2012-01-26 |
20120020940 | ANTIMICROBIAL PEPTIDES - The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amino acid residue; and A2, A6, A9, A10 each are a basic amino acid residue; A5 is an alanine or a basic amino acid residue; A3, A11 each are a basic amino acid residue, or a hydrophobic amino acid residue; or a peptidomimetic thereof; wherein the basic amino acid residues are selected from the group consisting of arginine, lysine and histidine; wherein the hydrophobic amino acid residues are selected from the group consisting of leucine, alanine, isoleucine, valine, methionine and phenylalanine; and wherein said peptide or peptidomimetic has antimicrobial and/or antiviral activity. Furthermore, the invention relates to a nucleic acid molecule encoding the peptide of the invention, a vector comprising the nucleic acid molecule as well as a host cell comprising the nucleic acid molecule or the vector. The present invention also relates to a method for producing the peptide of the invention, a composition as well as to the peptide or peptidomimetic of the invention for use in treating infectious diseases. | 2012-01-26 |
20120020941 | USE OF BLOOD GROUP STATUS III - Provided is a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. Further provided is a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. Further provided is a use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals. | 2012-01-26 |
20120020942 | Novel Lactobacillus Strains And Their Use Against Helicobacter Pylori - The invention concerns new isolated | 2012-01-26 |
20120020943 | Lactobacillus Plantarum and Uses Thereof - Provided is an isolated | 2012-01-26 |
20120020944 | USE OF A PROBIOTIC TO REGULATE BODY WEIGHT - The use of probiotic bacteria that modulate expression of a number of satiety markers in the intestine and reduces fat deposition to promote an optimal body weight of a mammal is described. The invention further relates to a composition comprising such a probiotic strain of bacteria and/or a fraction of said strain and/or metabolite of said strain for the preparation of a composition for administration to a mammal for promoting an optimal body weight of a mammal. | 2012-01-26 |
20120020945 | Food Supplement and Method for Enhancing Athletic Performance - Food supplements comprising | 2012-01-26 |